ReviewJournal of cancer research and clinical oncology2021
Role of lung and gut microbiota on lung cancer pathogenesis.
Review in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 2 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- [Fecal Microbiota Transplantation: A Promising Avenue for Lung Cancer Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Pooled it
- The Intriguing Connection Between the Gut and Lung Microbiomes.Pathogens (Basel, Switzerland) · 2024Pooled it
- Review
- Review
- Review
- Nutrition as Modulator of Oxidative Stress in Cancer Prevention and Treatment.International journal of molecular sciences · 2026Review
- Diabetes-associatedMicrobiology spectrum · 2026Observational
- The Role of Polyphenols in Respiratory and Gut Health: From the Perspective of Gut-Lung Axis.Phytotherapy research : PTR · 2026Review
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Decoding Microbiota-Immune Interplay in Viral Pathogenesis: Toward Next-Generation Antiviral Therapies.Probiotics and antimicrobial proteins · 2026Review
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Rosavin alleviates COPD via inhibition of IL-17-enriched NET formation and NF-κB signaling.Biology direct · 2026Article
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- Comparative analysis of the lung microbiota in patients with lung cancer, chronic obstructive pulmonary disease, and community-acquired pneumonia.Microbiology spectrum · 2026Article
- Enhanced recovery after surgery nursing pathway and prognosis assessment in lung cancer patients: A retrospective clinical study.Medicine · 2026Article
- Microbiota characteristics in different lung tissue sites of female patients with invasive adenocarcinoma.BMC microbiology · 2026Article
- A real-world evidence of sputum microbiota alterations and their association with oncogenomic changes and response to targeted therapies in patients with lung cancer.BMC microbiology · 2026Article
- Microbiome modulation of tumorigenesis and immune responses.Journal of biomedical science · 2026Review
- Gut Microbiome-Metabolite Interactions Contribute to Esophageal Cancer Risk: Evidence From Mendelian Randomization and Multiomics Integration.International journal of genomics · 2026Article
- The human microbiome in cancer: Not just a sidekick anymore.Genetics and molecular biology · 2026Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLung cancer is the leading cause of cancer-related deaths worldwide (Ferlay et al., Int J Cancer 136:E359-386, 2015). In addition, lung cancer is associated with the highest mortality among all cancer types (Wu et al., Exp Ther Med 16:3004-3010, 2018). Previous studies report that microbiota play an important role in lung cancer. Notably, changes in lung and gut microbiota, are associated with progression of lung cancer. Several studies report that lung and gut microbiome promote lung cancer initiation and development by modulating metabolic pathways, inhibiting the function of immune cells, and producing pro-inflammatory factors. In addition, some factors such as microbiota dysbiosis, affect production of bacteriotoxins, genotoxicity and virulence effect, therefore, they play a key role in cancer progression. These findings imply that lung and gut microbiome are potential markers and targets for lung cancer. However, the role of microbiota in development and progression of lung cancer has not been fully explored. PURPOSE: The aim of this study was to systemically review recent research findings on relationship of lung and gut microbiota with lung cancer. In addition, we explored gut-lung axis and potential mechanisms of lung and gut microbiota in modulating lung cancer progression.
conclusionPulmonary and intestinal flora influence the occurrence, development, treatment and prognosis of lung cancer, and will provide novel strategies for prevention, diagnosis, and treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.